Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.
MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23
Make sure you check these pages frequently, or sign up to our newsletter! To sign up for ESMO newsletters, create a myESMO account here and select the newsletters you’d like to receive.
New indications concern patients with previously untreated gastric or gastro-oesophageal junction adenocarcinoma and oesophageal squamous cell carcinoma
Findings from the NIAGARA study
Findings from the COMPASSION-16 study
Final invasive disease-free survival results from the NATALEE study
FDA also approved the VENTANA CLDN18 (43-14A) RxDx Assay as a companion diagnostic device
It is intended for the intraperitoneal treatment of malignant ascites
Findings from the SCRUM-Japan GOZILA study
Findings from the KEYNOTE-522 study
Findings from the PACE-B study
Evidence for efficacy is based on the results from the LIBRETTO-531 study
New indication concerns the treatment of patients with early breast cancer at high risk of recurrence
Findings from the SWOG S1011 study
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.
